effects [qlco]
Hormone replacement therapy [topp]
Fractures [inpo]
Height [orga]
Loss [qnco]
Heart study [diap]
Estrogen Replacement [topp]
Progestin [horm, phsu, strd]
Purpose [ftcn]
If [qlco]
Estrogen [horm, phsu, strd]
Plus [qlco]
Progestin [horm, phsu, strd]
Fractures [inpo]
height loss [fndg]
postmenopausal [tmco]
Women [popg]
Coronary Disease [dsyn]
Subject [grup]
Methods [inpr]
postmenopausal [tmco]
Women [popg]
Coronary Disease [dsyn]
Intact [qlco]
Uterus [bpoc]
Heart study [diap]
Estrogen Replacement [topp]
Progestin [horm, phsu, strd]
randomized controlled trial [inpr, resa]
DOUBLE BLIND [resa]
placebo [topp]
Secondary Prevention [topp]
Cardiovascular disease [dsyn]
Documented [hlca]
Fractures [inpo]
secondary [neop]
End Point [qlco]
height loss [fndg]
Vertebral Fracture [inpo]
Average [qnco]
Age [orga]
Women [popg]
Few [qnco]
Women [popg]
Osteoporosis [dsyn]
Based [ftcn]
Bone Density [clna]
Women [popg]
Assigned [ftcn]
mg% [qnco]
Conjugated Equine Estrogens [horm, phsu, strd]
2 5 [qnco]
mg% [qnco]
medroxyprogesterone acetate [horm, phsu, strd]
Tablet [bodm]
Daily [tmco]
N NOS [aapp, imft]
placebo [topp]
N NOS [aapp, imft]
Follow-up 1 year [fndg]
Average [qnco]
Assigned [ftcn]
hormone treatment [topp]
End [spco]
End [spco]
Study [mnob]
Person [popg]
Women [popg]
experience [menp]
Fracture [inpo]
treatment [ftcn]
Group [idcn]
Person [popg]
placebo [topp]
Group [idcn]
Person [popg]
Relative [famg]
Hazard [qlco]
P NOS [aapp, imft]
included [ftcn]
Wrist Fracture [inpo]
1-7 [gngm]
Hip Fractures [inpo]
2-3 [resa]
spine fracture [inpo]
Fractures [inpo]
Average [qnco]
height loss [fndg]
treatment [ftcn]
placebo [topp]
Group [idcn]
Percent [qnco]
Women [popg]
Lost [ftcn]
Height [orga]
treatment [ftcn]
Group [idcn]
placebo [topp]
Group [idcn]
Conclusions [idcn]
reduction [npop]
Fractures [inpo]
height loss [fndg]
Old [tmco]
Women [popg]
Select [acty]
Osteoporosis [dsyn]
randomized [resa]
Needed [qlco]
Clarify [acty]
Hormone replacement therapy [topp]
Fracture [inpo]
Women [popg]
Osteoporosis [dsyn]
